Pivagabine
 | |
| Names | |
|---|---|
| IUPAC name
4-(2,2-Dimethylpropanoylamino)butanoic acid | |
| Identifiers | |
| ATC code | N06 |
69542-93-4  | |
| ChemSpider | 62118 |
| EC number | 274-038-3 |
| |
| Jmol-3D images | Image Image |
| KEGG | D07342 |
| MeSH | N-trimethylacetyl-4-aminobutyric+acid |
| PubChem | 68888 |
| |
| UNII | C53SV0WO4V |
| Properties | |
| Molecular formula |
C9H17NO3 |
| Molar mass | 187.24 g·mol−1 |
| Pharmacology | |
| Oral | |
| Elimination half-life |
6.4 hours |
| Legal status |
|
| Related compounds | |
| Related alkanoic acids |
|
| Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
| Infobox references | |
Pivagabine (Tonerg) is an antidepressant and anxiolytic drug which was introduced in Italy in 1997 for the treatment of depressive and maladaptive syndromes. But it was discontinued in Italy (according to Martindale). Originally believed to function as a prodrug to GABA,[1] pivagabine is now believed to act via its inhibitory effects on corticotropin-releasing factor (CRF).[2][3][4][5]
See also
References
- ↑ Bianchi M, Quadro G, Mourier G, Galzigna L (1983). "Pharmacokinetics and in vitro effects of a 4-aminobutyric acid derivative with anticonvulsant action". Pharmacology 27 (4): 237–40. doi:10.1159/000137876. PMID 6634934.
- ↑ Scapagnini U, Matera M (November 1997). "Effects of pivagabine on psychophysical performance and behavioural response in experimental models of stress". Arzneimittel-Forschung 47 (11A): 1310–4. PMID 9450154.
- ↑ Esposito G, Luparini MR (November 1997). "Pivagabine: a novel psychoactive drug". Arzneimittelforschung 47 (11A): 1306–9. PMID 9450153.
- ↑ Gerra G, Zaimovic A, Giusti F et al. (July 2001). "Pivagabine effects on neuroendocrine responses to experimentally-induced psychological stress in humans". Behavioural Brain Research 122 (1): 93–101. doi:10.1016/S0166-4328(01)00177-2. PMID 11287080.
- ↑ Serra M, Concas A, Mostallino MC et al. (April 1999). "Antagonism by pivagabine of stress-induced changes in GABAA receptor function and corticotropin-releasing factor concentrations in rat brain". Psychoneuroendocrinology 24 (3): 269–84. doi:10.1016/S0306-4530(98)00049-3. PMID 10101733.
| ||||||||||||||||||||||||||||||||||||||||||||